Close Menu

NEW YORK (360Dx) – Vermillion reported after the close of the market on Tuesday that its fourth quarter revenues fell just under 1 percent year over year.

The company reported Q4 revenues of $798,000, down from $805,000 in Q4 2016.

Vermillion posted $658,000 in product revenues from sales of its OVA1 ovarian cancer test, down 3 percent from $680,000 in the prior-year quarter. Service revenue from its Aspira IVD business was up 12 percent to $140,000 from $125,000 in Q4 2016.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.